Nanotechnology and Matrix Metalloproteinases in Cancer Diagnosis and Treatment.
cancer
matrix metalloproteinases
metastasis nanoparticles
nanotechnology
nanotheranostic
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
04
2022
accepted:
18
05
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
21
6
2022
Statut:
epublish
Résumé
Cancer is still one of the leading causes of death worldwide. This great mortality is due to its late diagnosis when the disease is already at advanced stages. Although the efforts made to develop more effective treatments, around 90% of cancer deaths are due to metastasis that confers a systemic character to the disease. Likewise, matrix metalloproteinases (MMPs) are endopeptidases that participate in all the events of the metastatic process. MMPs' augmented concentrations and an increased enzymatic activity have been considered bad prognosis markers of the disease. Therefore, synthetic inhibitors have been created to block MMPs' enzymatic activity. However, they have been ineffective in addition to causing considerable side effects. On the other hand, nanotechnology offers the opportunity to formulate therapeutic agents that can act directly on a target cell, avoiding side effects and improving the diagnosis, follow-up, and treatment of cancer. The goal of the present review is to discuss novel nanotechnological strategies in which MMPs are used with theranostic purposes and as therapeutic targets to control cancer progression.
Identifiants
pubmed: 35720130
doi: 10.3389/fmolb.2022.918789
pii: 918789
pmc: PMC9198274
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
918789Informations de copyright
Copyright © 2022 Gonzalez-Avila, Sommer, García-Hernandez, Ramos and Flores-Soto.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Science. 2016 Apr 8;352(6282):175-80
pubmed: 27124451
Adv Exp Med Biol. 2021;1309:1-22
pubmed: 33782866
Analyst. 2013 Jan 21;138(2):410-6
pubmed: 23150876
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33601416
Trends Biotechnol. 2017 Dec;35(12):1169-1180
pubmed: 28965747
J Breast Cancer. 2011 Jun;14(2):88-95
pubmed: 21847402
Chem Soc Rev. 2019 Apr 1;48(7):2053-2108
pubmed: 30259015
Theranostics. 2017 Jan 7;7(3):538-558
pubmed: 28255348
Exp Cell Res. 2007 Apr 1;313(6):1181-91
pubmed: 17335808
Theranostics. 2017 Jul 8;7(11):2878-2887
pubmed: 28824722
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15431-6
pubmed: 22949663
Eur Respir J. 2011 Jul;38(1):191-208
pubmed: 21177845
Mol Pharm. 2014 Aug 4;11(8):2755-63
pubmed: 24983928
FEBS Lett. 2008 Jul 23;582(17):2615-9
pubmed: 18588890
Cancer Metastasis Rev. 2014 Dec;33(4):1043-57
pubmed: 25325988
Nanomedicine (Lond). 2019 Dec;14(24):3127-3142
pubmed: 31855120
Oncotarget. 2016 Feb 2;7(5):5598-612
pubmed: 26734996
Pharmacol Res. 2016 Nov;113(Pt A):515-520
pubmed: 27687955
PLoS One. 2013 Jul 19;8(7):e69354
pubmed: 23894455
J Mater Chem B. 2018 Jul 14;6(26):4314-4325
pubmed: 32254507
Nanoscale Res Lett. 2021 May 20;16(1):88
pubmed: 34014432
J Biol Chem. 2008 Mar 7;283(10):6232-40
pubmed: 18174174
Mater Sci Eng C Mater Biol Appl. 2021 Apr;123:112027
pubmed: 33812642
Cancer Cell Microenviron. 2015 Apr 26;2(2):e773
pubmed: 26023680
Bioeng Transl Med. 2016 Jun 03;1(1):10-29
pubmed: 29313004
Cell Mol Life Sci. 2015 Nov;72(21):4111-26
pubmed: 26210152
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Semin Cancer Biol. 2019 Jun;56:100-115
pubmed: 29155240
Breast Cancer Res. 2018 Dec 17;20(1):154
pubmed: 30558648
Bioconjug Chem. 2014 Mar 19;25(3):601-10
pubmed: 24506683
Toxicol Appl Pharmacol. 2016 Nov 1;310:98-107
pubmed: 27634460
J Biol Chem. 1995 Aug 4;270(31):18506-11
pubmed: 7629179
Clin Exp Metastasis. 2013 Mar;30(3):289-97
pubmed: 23053742
Drug Deliv. 2021 Dec;28(1):1055-1066
pubmed: 34078185
Mol Cancer Ther. 2018 Jun;17(6):1147-1155
pubmed: 29735645
Int J Biol Markers. 2013 Jun 28;28(2):117-30
pubmed: 23787494
Methods Mol Biol. 2018;1731:325-348
pubmed: 29318564
Nanomedicine (Lond). 2019 Jul;14(14):1791-1804
pubmed: 31305218
J Control Release. 2018 Jan 10;269:52-62
pubmed: 29113793
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
J Cell Sci. 2006 Sep 15;119(Pt 18):3856-65
pubmed: 16940349
Adv Exp Med Biol. 2021;1295:121-134
pubmed: 33543458
Matrix Biol. 2007 Oct;26(8):587-96
pubmed: 17669641
Nat Cell Biol. 2007 Dec;9(12):1392-400
pubmed: 18037882
Prog Mol Biol Transl Sci. 2017;147:1-73
pubmed: 28413025
ACS Nano. 2017 Mar 28;11(3):2313-2381
pubmed: 28290206
Trends Pharmacol Sci. 2018 Aug;39(8):766-781
pubmed: 30032745
Drug Des Devel Ther. 2020 Oct 23;14:4465-4475
pubmed: 33122890
ACS Appl Mater Interfaces. 2016 May 25;8(20):12609-19
pubmed: 27153187
BMC Cancer. 2013 Apr 01;13:171
pubmed: 23548172
Crit Rev Oncol Hematol. 2004 Mar;49(3):187-98
pubmed: 15036259
Cell Oncol (Dordr). 2021 Oct;44(5):1087-1103
pubmed: 34319576
Int J Cancer. 2016 Mar 1;138(5):1058-66
pubmed: 25784597
Nat Commun. 2017 May 19;8:14998
pubmed: 28524865
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Nanotheranostics. 2018 May 23;2(3):233-242
pubmed: 29868348
Adv Healthc Mater. 2017 Nov;6(22):
pubmed: 28885787
ACS Nano. 2021 Feb 23;15(2):2099-2142
pubmed: 33497197
Expert Opin Drug Metab Toxicol. 2016;12(2):191-200
pubmed: 26852787
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1412-1426
pubmed: 31773232
Nature. 2005 Jul 7;436(7047):123-7
pubmed: 16001073
J Microencapsul. 2017 Aug;34(5):440-453
pubmed: 28617063
Rom J Morphol Embryol. 2010;51(2):215-28
pubmed: 20495735
Tumour Biol. 2015 Sep;36(9):6883-9
pubmed: 25851348
Stem Cells Dev. 2014 Aug 15;23(16):1870-82
pubmed: 24738865
Matrix Biol. 2015 May-Jul;44-46:207-23
pubmed: 25794647
Cancers (Basel). 2015 Oct 14;7(4):2054-62
pubmed: 26473929
APMIS. 1999 Jan;107(1):38-44
pubmed: 10190278
Carcinogenesis. 2010 Jul;31(7):1175-84
pubmed: 19892798
Int J Mol Sci. 2020 Jul 02;21(13):
pubmed: 32630820
Genes Dev. 2016 Apr 15;30(8):892-908
pubmed: 27083997
Cell Death Dis. 2018 Mar 7;9(3):382
pubmed: 29515112
Cancer Med. 2019 Sep;8(12):5574-5576
pubmed: 31397113
J Biol Chem. 2013 Mar 1;288(9):6451-64
pubmed: 23300077
Adv Exp Med Biol. 2020;1245:97-131
pubmed: 32266655
Drug Deliv. 2019 Dec;26(1):744-755
pubmed: 31340676
Cancer Metastasis Rev. 2007 Jun;26(2):319-31
pubmed: 17458507
Cell Mol Life Sci. 2014 Apr;71(7):1191-210
pubmed: 23912897
Exp Dermatol. 2014 Jul;23(7):457-63
pubmed: 24815015
Cancer Biol Ther. 2010 Jul 15;10(2):198-208
pubmed: 20534975
Oncotarget. 2015 Sep 29;6(29):28132-50
pubmed: 26320173
Biomed Pharmacother. 2018 Oct;106:1098-1107
pubmed: 30119176
Int J Oncol. 2007 Apr;30(4):793-802
pubmed: 17332917
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4311-6
pubmed: 20160077
Biosens Bioelectron. 2017 Mar 15;89(Pt 1):666-672
pubmed: 26725932
J Cell Biol. 2018 Jul 2;217(7):2291-2298
pubmed: 29915025
Adv Sci (Weinh). 2018 Jun 10;5(8):1700867
pubmed: 30128224
J Invest Dermatol. 2011 Jun;131(6):1322-30
pubmed: 21307877
Signal Transduct Target Ther. 2019 Aug 9;4:26
pubmed: 31637006
J Pathol. 2015 Apr;235(5):773-83
pubmed: 25469981
Biochim Biophys Acta. 2010 Jan;1803(1):20-8
pubmed: 19374923
ACS Sens. 2018 Aug 24;3(8):1522-1530
pubmed: 30015475
Anticancer Res. 2017 Jun;37(6):2867-2873
pubmed: 28551623
Crit Rev Oncol Hematol. 2016 Jan;97:303-11
pubmed: 26467073
Cancer Sci. 2011 Apr;102(4):815-27
pubmed: 21219539
Nanoscale. 2015 Jan 14;7(2):440-4
pubmed: 25418982
Front Oncol. 2014 Dec 18;4:366
pubmed: 25566504
Nanoscale. 2018 May 31;10(21):9935-9948
pubmed: 29770822
Theranostics. 2020 Jan 1;10(1):91-108
pubmed: 31903108
Acta Biomater. 2018 Mar 15;69:277-289
pubmed: 29369806
Mol Carcinog. 2011 Oct;50(10):770-80
pubmed: 21751260
Med Sci Monit. 2019 Sep 25;25:7202-7208
pubmed: 31587013
Hum Genomics. 2010 Feb;4(3):194-201
pubmed: 20368140
J Cell Sci. 2001 Jan;114(Pt 1):111-118
pubmed: 11112695
Drug Deliv. 2019 Dec;26(1):1280-1291
pubmed: 31793355
Acta Med Okayama. 2012;66(5):399-407
pubmed: 23093058
Clin Cancer Res. 2010 Dec 15;16(24):5928-35
pubmed: 20962028
Front Oncol. 2021 May 07;11:672195
pubmed: 34026650
J Pers Med. 2021 Aug 06;11(8):
pubmed: 34442415
Cancer Res. 2007 Mar 1;67(5):2030-9
pubmed: 17332331
Chem Rev. 2017 Sep 13;117(17):11476-11521
pubmed: 28862437
Arch Pharm Res. 2020 Jan;43(1):22-31
pubmed: 31989479
Anal Sci. 2017;33(2):137-142
pubmed: 28190830
ACS Appl Mater Interfaces. 2017 May 3;9(17):14596-14605
pubmed: 28397487
Crit Rev Oncol Hematol. 2019 May;137:57-83
pubmed: 31014516
Adv Cancer Res. 2015;128:141-71
pubmed: 26216632
ACS Appl Bio Mater. 2020 Mar 16;3(3):1394-1405
pubmed: 35021632
Cells. 2019 Feb 27;8(3):
pubmed: 30818851
Cancer Res. 2003 Mar 1;63(5):1138-43
pubmed: 12615733
Curr Pharm Des. 2020;26(42):5503-5517
pubmed: 33200696
Molecules. 2019 Dec 27;25(1):
pubmed: 31892180
Front Bioeng Biotechnol. 2020 May 25;8:503
pubmed: 32523946
Anal Chem. 2012 Feb 7;84(3):1466-73
pubmed: 22242647
Cancer Metastasis Rev. 2019 Jun;38(1-2):103-112
pubmed: 31069574
Acta Biomater. 2019 Apr 15;89:289-299
pubmed: 30851455
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt A):2001-2014
pubmed: 28435009